サンプル依頼リスト カート
  • English
  • Korean
表紙：免疫腫瘍アッセイの世界市場-2023年～2030年
市場調査レポート
商品コード
1373363

免疫腫瘍アッセイの世界市場-2023年～2030年

Global Immuno Oncology Assays Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
免疫腫瘍アッセイの世界市場-2023年～2030年
出版日: 2023年10月18日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

免疫腫瘍学は、がんにおける免疫系に焦点を当て、限局がんや進行転移がんにおいてより良い結果を示します。現在、新規免疫生物学的治療法を開発するために250以上の臨床試験が進行中であり、特定のがん種やその転移の診断に役立ついくつかのアッセイも開発中です。

これらのアッセイは、継続的でリアルタイムのがん細胞増殖と転移の分析に役立ちます。殺細胞アッセイ、細胞増殖アッセイ、その他の免疫細胞検出アッセイなどの複数のアッセイは、個人の特定のがんタイプの検出に役立ちます。

スコープ

市場力学：市場促進要因と市場抑制要因

免疫腫瘍分野における開発の増加

がんの診断と治療の可能性を広げるための免疫腫瘍学検査の開発。さまざまな助成金を受けた新製品の発売は、がん研究を加速させ、他の種類のがんに罹患している人々のより良いがん治療に役立っています。主な焦点は、メラノーマや大腸がんなどです。例えば、2022年5月、Labcorp社は、メラノーマで観察される腫瘍の免疫組織化学（IHC）による遺伝子発現レベルを測定する新しい検査を開始しました。

2022年11月、アコヤ・バイオサイエンシズ社はハイスループット空間バイオマーカー探索のためのPhenoCode Signature Panelsを発売しました。これにより、免疫腫瘍学への応用に向けた予測バイオマーカーの開発と検証が加速されます。

2022年3月、ルナフォアは、免疫腫瘍学ポートフォリオの確立に役立つ空間生物学技術の導入を検討している研究室にユニークな機会を提供するため、2023年SPYRE免疫腫瘍学助成金プログラムを宣言しました。

2022年5月、ベラサイト社は、転移性結腸直腸がん（mCRC）患者を同定する同社のImmunoscore免疫チェックポイント（IC）アッセイを示す新しいデータを発表しました。

さらに、がん治療に関する研究の増加、さまざまな診断方法に関する意識の高まり、進歩は、今後一定期間の市場を牽引するいくつかの要因です。

専門知識の不足

免疫腫瘍学は常に進化しているため、免疫腫瘍学に関する基礎知識がなく、アッセイの取り扱いや分析に関する知識の不足は時間の経過とともに増加します。データ解析には、免疫学と腫瘍学の両分野における強力な専門知識が必要です。そうでないと、偽陽性や偽陰性を示す誤った結果が出たり、結果が検出できなかったりする可能性があります。確立された手順がないため、標準的な免疫検査手順よりもエラー率が高くなります。

さらに、アッセイにおけるエラー、熟練した専門家の不足は、今後一定期間の市場を阻害する数少ない要因です。

このレポートの詳細について- サンプル請求

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 免疫オンコロジー分野における開発の増加
      • 抑制要因
    • 抑制要因
      • 専門知識の不足
      • YY
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • DMI意見

第6章 COVID-19分析

第7章 製品・サービス別

  • インスツルメンツ
  • 消耗品
  • ソフトウェアとサービス

第8章 アッセイタイプ別

  • 細胞増殖アッセイ
  • 細胞遊走および浸潤アッセイ
  • 貪食アッセイ
  • 免疫細胞死滅アッセイ
  • その他

第9章 テクノロジー別

  • PCR法
  • NGS
  • ISH
  • イムノアッセイ
  • フローサイトメトリー
  • その他

第10章 適応症別

  • 大腸がん
  • 乳がん
  • 肺がん
  • 黒色腫
  • その他

第11章 エンドユーザー別

  • 学術機関
  • 研究機関
  • 診断センター
  • その他

第12章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第13章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第14章 企業プロファイル

  • Merck KGaA
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Thermo Fisher Scientific Inc.
  • Crown Bioscience
  • Lunaphore Technologies SA.
  • Eve Technologies.
  • Vivia Biotech S.L
  • Illumina, Inc.
  • Bio-Rad Laboratories, Inc
  • Charles River Laboratories
  • PerkinElmer Inc.

第15章 付録

目次
Product Code: PH1613

Overview

Immuno-oncology focuses on the immune system in cancer, which shows better results in localized and advanced metastatic cancers. Over 250 clinical trials are currently in progress to develop novel immunobiological treatments, and several assays are in the pipeline that help in diagnosing specific cancer types and their metastasis.

These assays are helpful in continuous and real-time cancer cell proliferation and metastasis analysis. Multiple assays, such as cell killing assays, cell proliferation assays, and other immune cell detection assays, help detect specific cancer types in individuals.

Scope

Market Dynamics: Drivers & Restraints

Increasing developments in immuno oncology sector

Developments in immuno oncology testing in an attempt to increase the prospects of cancer diagnosis and treatment. Launch of new products coming up with different grants speed up cancer research, which is helpful for better cancer treatment for individuals suffering from other types of cancers. The main focus is on melanoma, colorectal cancers, etc., as these are observed in most individuals. For instance, in May 2022, Labcorp launched a new test to measure gene expression levels by immunohistochemistry (IHC) in tumors observed in melanoma.

In November 2022, Akoya Biosciences, Inc. launched PhenoCode Signature Panels for high-throughput spatial biomarker discovery. This accelerates the development and validation of predictive biomarkers for immuno-oncology applications.

In March 2022, Lunaphore declared a 2023 SPYRE Immuno-Oncology Grant Program to provide a unique opportunity for the laboratories looking to adopt spatial biology technology that helps establish an immuno-oncology portfolio.

In May 2022, Veracyte, Inc. declared new data showing the company's Immunoscore Immune Checkpoint (IC) assay, which identifies patients with metastatic colorectal cancer (mCRC).

Furthermore, increased research focus on cancer therapy, rising awareness about different diagnosis procedures, and advancements are a few factors that drive the market in the forthcoming period.

Lack of expertise

Immuno-oncology is constantly evolving, and hence, the deficit in the knowledge of handling and analyzing the assays will increase over time as there is no basic knowledge of immuno-oncology. The data analysis requires strong expertise in both the immunology and oncology sectors. Otherwise, there is a possibility of false outcomes that show false positive or false negative results, or the results cannot be detected. There are no established procedures, so the error rate is higher than in standard immuno-testing procedures.

Furthermore, errors in assays, lack of skilled professionals are few factors that hamper the market in the forthcoming period.

For more details on this report - Request for Sample

Segment Analysis

The global immuno-oncology assays are segmented based on products and services, assay type, technology, indication, end user and region.

The Immunoassay segment accounted for approximately 48.6% of the market share

The immunoassay segment is expected to hold the largest share of the market. Immuno-oncology has become an exciting approach to cancer treatment due to its specificity and durability. The assays like immuno-cell killing assays, cell proliferation assays, and next-generation sequencing assays are developed as their approach is exact and accurate in finding and treating the disease more precisely before the cancer undergoes metastasis. Hence, new immuno-oncology assay launches help increase the specificity for detecting cancer metastasis.

In April 2023, Agilent Technologies Inc. launched Agilent SureSelect Cancer CGP Assay, an NGS assay for advancing precision immuno-oncology. It helps in profiling a broad range of tumor types.

In January 2022, Oncocyte declared that it had agreed with Thermo Fisher Scientific to validate Oncomine Comprehensive Assay Plus clinically. This agreement aims to develop the DetermaIO test that may predict responses to immuno-oncology therapies.

Geographical Analysis

North America accounted for approximately 40.5% of the market share in 2022

North America is expected to hold the largest market share owing to the prevalence of cancer cases in the US and expenditure for cancer care. Significant players like Thermo Fisher Scientific, Lunafore, etc., are continuously working on launching new immune-oncology assays shortly, as a few of them are still in the testing stage, which will be released soon.

According to the JAMA Health Forum, 2022, US cancer care spending has followed a similar pattern, surpassing $200 billion in 2020. National cancer care expenditures were high in the US compared to the other 22 countries. This spending is expected to increase to improve cancer care outcomes.

According to the American Cancer Society journal, In 2022, an estimated 1.9 million new cancer cases will be diagnosed and 609,360 cancer deaths in the United States alone.

COVID-19 Impact Analysis:

COVID-19 has shown an impact on the immuno-oncology assay market. Due to the implementation of lockdowns worldwide, most specialty diagnostic centers have shut down or stopped the services that provide immuno-oncology testing due to the surge in COVID-19 in the mid-pandemic phase. People restricted themselves from getting tested because they feared contracting the disease. Most of the testing procedures were halted and postponed to later stages. Due to the rise in COVID-19 cases, there was a shift in the focus of manufacturing COVID-19 testing kits for disease diagnosis.

Competitive Landscape

The major global players in the immuno oncology assays market include: Merck KGaA, Thermo Fisher Scientific Inc., Crown Bioscience, Lunaphore Technologies SA., Eve Technologies., Vivia Biotech S.L, Illumina, Inc., Bio-Rad Laboratories, Inc, Charles River Laboratories, PerkinElmer Inc. among others.

Key Developments

In April 2023, ANGLE plc, a world-leading liquid biopsy company signed a contract with Crescendo Biologics Limited, a clinical-stage immuno-oncology company. Crescendo is planning to use a recently launched flex assay developed by ANGLE for the treatment of patients with PSMA positive solid tumors.

In September 2023, Cytek Biosciences, Inc. launched a global road show called Cytek Reveal that is to be held on October 5th, 2023. The company's patented Full Spectrum Profiling (FSP) technology empowers scientists to work on immuno-oncology testing solutions.

In May 2023, Memorial Sloan Kettering Cancer Center (MSK) declared $40M for Marie-Josee Kravis Center for Cancer Immunobiology (CCI). This creation of an immuno-oncology hub helps in progressing immuno-oncology discovery, cell engineering, immuno-diagnostic assays, etc.

Why Purchase the Report?

  • To visualize the global immuno oncology assays market segmentation based on products and services, assay type, technology, indication, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of immuno oncology assays market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global immuno oncology assays market report would provide approximately 77 tables, 84 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Products and Services
  • 3.2. Snippet by Assay Type
  • 3.3. Snippet by Technology
  • 3.4. Snippet by Indication
  • 3.5. Snippet by End User
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Driver
      • 4.1.1.1. Increasing developments in immune-oncology sector
      • 4.1.1.2.
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of Expertise
      • 4.1.2.2.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Products and Services

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
    • 7.1.2. Market Attractiveness Index, By Products and Services
  • 7.2. Instruments*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Consumables
  • 7.4. Software and Services

8. By Assay Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
    • 8.1.2. Market Attractiveness Index, By Assay Type
  • 8.2. Cell proliferation assays*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Cell migration and invasion assays
  • 8.4. Phagocytosis assays
  • 8.5. Immune cell killing assays
  • 8.6. Others

9. By Technology

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.1.2. Market Attractiveness Index, By Technology
  • 9.2. PCR*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. NGS
  • 9.4. ISH
  • 9.5. Immunoassay
  • 9.6. Flow cytometry
  • 9.7. Others

10. By Indication

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.1.2. Market Attractiveness Index, By Indication
  • 10.2. Colorectal cancer*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Breast Cancer
  • 10.4. Lung Cancer
  • 10.5. Melanoma
  • 10.6. Others

11. By End User

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.1.2. Market Attractiveness Index, By End User
  • 11.2. Academic Institutes*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Research Organizations
  • 11.4. Diagnostics centers
  • 11.5. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. UK
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Assay Type
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Market Positioning/Share Analysis
  • 13.3. Mergers and Acquisitions Analysis

14. Company Profiles

  • 14.1. Merck KGaA
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Thermo Fisher Scientific Inc.
  • 14.3. Crown Bioscience
  • 14.4. Lunaphore Technologies SA.
  • 14.5. Eve Technologies.
  • 14.6. Vivia Biotech S.L
  • 14.7. Illumina, Inc.
  • 14.8. Bio-Rad Laboratories, Inc
  • 14.9. Charles River Laboratories
  • 14.10. PerkinElmer Inc.

LIST NOT EXHAUSTIVE.

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us